

GenomeQuest CMDx Grant Applications
Excerpts of Benefits -- Better, Cheaper, Faster, More

... advance patient care by providing more cost effective comprehensive, accurate and predictive personalized genomics based testing for genetic and infectious diseases.

... consolidate and expand our existing single gene testing

... cost saving of approximately \$400,000 annually to our healthcare system

... will be more cost effective and efficient for the patient's care

... lower cost per gene/disease for patients

... reduce our turnaround time for sequencing based assays from months to weeks

... support testing for many more rare disorders

... allow faster diagnosis because all genes known to give certain phenotypes will be screened simultaneously

... earlier and more sensitive bacterial identification, early detection of emerging resistant strains

... advantages of economy and scale to interrogate many genes "simultaneously"

... more comprehensive, accurate, predictive, and especially more affordable genetic testing services

... maintain our future market competitiveness

... affordability, fast turn-around-time, more rapid test development and validation, enhance the accuracy and timeliness of reporting results to providers

... position us as a competitive and state-of-the-art molecular diagnostics laboratory in the clinical diagnostics market

... expand our current test menu to include more rare genes, thus increasing the number of patients for which a diagnosis will be made

... decrease the cost and time to achieve results for patients, reduce need for invasive testing

... more comprehensively test patients for cancer related targets simultaneously, without necessitating the collection/shipping of many individual samples

... higher sensitivity, which can increase our ability to produce a meaningful result for these patients, especially when samples have a low tumor content

... expand and streamline our molecular genetics laboratory

... provide more comprehensive testing through the examination of more rare causative genes

... the additional cost [of observing more genes] is vanishingly small

... help communication between the laboratory and our external clients

... eliminate the need for these [multiple] communications, which often prolong the testing period, and will make test billing more straightforward

... added confidence that they have tested all possible underlying genetic defects

... being the first medical center to offer an NGS panel for these disorders seems appropriate

... reduce the number of patient blood draws and incorporate new genes as research moves into clinical

... decrease the turnaround time so patients will have their results quicker

... increase the sensitivity of our diagnostics, either by covering genes more deeply or sequencing more genes

... open tremendous opportunities for personalized medicine in cancer

... decrease direct genetic analysis and therapeutic cost

... more rapid and appropriate diagnostic testing and will provide important information to physicians and families

... play an important role in the evaluation and management of both the affected individual as well as their family members, allows the most appropriate medical surveillance

... offer comprehensive genetic testing that would not be otherwise feasible due to the time, labor, and expense of testing

... reduce the hands on processing time by streamlining and automating much of the initial labor including amplification and sequencing

... remove this (lack of expertise) barrier because of the comprehensive/standard nature of testing

... increase the diagnostic yield and decrease the time to diagnosis as compared to a tiered testing strategy

... business volume and the quality of care by our healthcare partners will be improved

... increase the number of cardiomyopathy genes tested four-fold

... increase the number of genes on our congenital heart disease panels

... speed the delivery of genome based diagnostics to the patients

... the expanded gene panels, faster turn-around-time, and lower test cost will attract more business for our lab

... provide more accurate interpretation for our healthcare partners

... providing new clinical genetic tests for disorders where no clinical testing is currently available

... more completely understand the genetic basis of rare clinical disorders

... expand our testing menu of sequencing tests for inherited disorders

... more academic discussion regarding sequencing results

... reduce the costs of "send-out" sequencing tests borne by our healthcare system

... rapidly translate these novel research findings into clinically relevant tests

... cost savings over conventional methods will also be welcomed by both health care practitioners and patients alike

... promises to be an area of economic growth for our laboratory

... provide much more comprehensive test at the same price level

... increase in diagnostic yield will make our laboratory more competitive and enlist more hospitals and practice groups

... test more genes for more indications and therefore increase the number of the tests in our menu

... receive more grant funding for our clinical laboratory services

... cover a wide-range of genetic defects including both point mutations and deletions

... reduce labor costs and reduce errors

... decreased waiting times for test results

... provide more comprehensive genetic evaluations for diseases

... enhance our ability and reduce the time to validate disease panels and bring tests to the medical community

... reduce the cost of genetic testing for third-party carriers and the patients

.. enable testing for multiple diseases in the same category simultaneously thus markedly reducing the cost of diagnostic testing

... reduced cost and shorter turn around time

... decrease the turn around time of test resulting

... more rapidly confirm or negate diagnoses

... draw a larger patient pool in search of cutting edge genetic testing thus increasing the patient volumes in our clinical department

... draw samples from outside clients for testing, increasing the test volumes and lab productivity

... reduce the cost of testing to about \$400 (from "thousands") or less per case for all associated genes and will take only about 4 weeks

... make testing accessible to most patients, allowing them to reap the full benefit of understanding their disease at a molecular level

... make labs more attractive and ready to adopt projects from the industry

... make labs more competitive in revenues and scientific production.

... labs can better network and share skills